Login to Your Account

Corcept Shares Jump as Korlym Wins First Cushing's Approval

By Staff Reports

Tuesday, February 21, 2012

Shares of Corcept Therapeutics Inc. jumped nearly 50 percent aftermarket on Friday as news began to spread that the Menlo Park, Calif.-based biotech had won FDA approval of Korlym (mifepristone) to treat hyperglycemia in patients with Cushing's syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription